Fungal DiseasesNCT07783971
Study on the Microbial Environment of Non-small Cell Lung Cancer Based on Mycogenomics and Its Clinical Relevance
An observational study of Fungal Diseases and Lung Cancer (NSCLC), run by 958th Army Hospital of the Chinese People's Liberation Army at 1 site in China.
Trial summary
This study aims to uncover the characteristics of the fungal flora in non-small cell lung cancer, and to investigate the relationship between pulmonary fungi and the various pathological subtypes, stages, clinical features of non-small cell lung cancer, as well as patient prognosis. Read more about this study
- Who is it for?
- Ages 30 to 80 years
- Conditions the study is for
- Fungal Diseases, Lung Cancer (NSCLC), Microbioata
- How many people
- 10 participants
- Where
- 1 siteChina
- Study dates
- 1 Aug 2026to 1 Aug 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The research object is the patients who are newly diagnosed as "non-small cell lung cancer" and intend to undergo surgical resection
Who may be able to join
- Non-small cell lung cancer was diagnosed by biopsy before operation, frozen pathology during operation or paraffin section after operation; The patients were 30 to 80 years old; No chemotherapy, radiotherapy, targeted therapy or immunotherapy were given before operation;
Who cannot join
- Patients who do not meet the inclusion criteria; Combined with primary malignant tumor of other systems or recurrence of lung cancer, combined with immunodeficiency disease; Acute exacerbation of chronic obstructive pulmonary disease, bronchial asthma, bronchiectasis with infection, tuberculosis and pneumoconiosis; recent use of antifungal drugs; Basic clinical information (such as pathological type, clinical stage and treatment plan) cannot be obtained;
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
958th Army Hospital
Chongqing, Liangjiang New, 400020
shunhong wang project leader, 023-68762084, wangshunhong918@163.com
About this study
This study aims to uncover the characteristics of the fungal flora in non-small cell lung cancer, and to investigate the relationship between pulmonary fungi and the various pathological subtypes, stages, clinical features of non-small cell lung cancer, as well as patient prognosis. It seeks to provide new perspectives for a comprehensive understanding of non-small cell lung cancer, as well as new approaches for its early diagnosis and prognosis assessment.
Read the detailed description
This project intends to study the structural characteristics and clinical relevance of fungal microbiota in lung tissue of patients with non-small cell lung cancer. The project plans to collect 500 lung tissue samples from patients undergoing lung cancer surgery, build an ecological map of non-small cell lung cancer fungi through high-throughput sequencing, and simultaneously carry out traditional fungi culture to obtain culturable strain resources, so as to build a resource bank of non-small cell lung cancer fungi. By integrating clinicopathological information and follow-up data, using bioinformatics and statistical methods, key landmark fungi were screened, and the correlation between fungal community structure and different pathological subtypes, stages and clinical characteristics of non-small cell lung cancer was analyzed.
This project intends to study the structural characteristics and clinical relevance of fungal microbiota in lung tissue of patients with non-small cell lung cancer. The project plans to collect 500 lung tissue samples from patients undergoing lung cancer surgery, build an ecological map of non-small cell lung cancer fungi through high-throughput sequencing, and simultaneously carry out traditional fungi culture to obtain culturable strain resources, so as to build a resource bank of non-small cell lung cancer fungi. By integrating clinicopathological information and follow-up data, using bioinformatics and statistical methods, key landmark fungi were screened, and the correlation between fungal community structure and different pathological subtypes, stages and clinical characteristics of non-small cell lung cancer was analyzed.
- Conditions
- Fungal Diseases, Lung Cancer (NSCLC), Microbioata
- Keywords
- the lung microbiome
- Medical subject headings
- Mycoses, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Lung cancer group | The samples included in this group were lung cancer tissues. | |
| Normal lung tissue group | The samples included in this group were normal lung tissues. |
What is being measured
The primary outcome is the main question the study is designed to answer.
the fungal microbial environment
Different fungal microbial environments were observed in different parts of lung tissue.
Measured: baseline, pre-surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Aug 2026
- Study start1 Aug 2026
- Primary completion30 Jan 2028 (estimated)
- Study completion1 Aug 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Fungal DiseasesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Retrospective
- Enrolment
- 10 participants (estimated)
Sponsor and investigators
- Lead sponsor
- 958th Army Hospital of the Chinese People's Liberation Army
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, youlinghou, 958th Army Hospital of the Chinese People's Liberation Army
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07783971
- Sponsor's protocol ID
- microbial environment
- Status last verified
- Aug 2026
- First submitted
- 1 Aug 2026
- Last updated
- 25 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Dohlman AB, Klug J, Mesko M, Gao IH, Lipkin SM, Shen X, Iliev ID. A pan-cancer mycobiome analysis reveals fungal involvement in gastrointestinal and lung tumors. Cell. 2022 Sep 29;185(20):3807-3822.e12. doi: 10.1016/j.cell.2022.09.015.
PubMed 36179671Liu NN, Yi CX, Wei LQ, Zhou JA, Jiang T, Hu CC, Wang L, Wang YY, Zou Y, Zhao YK, Zhang LL, Nie YT, Zhu YJ, Yi XY, Zeng LB, Li JQ, Huang XT, Ji HB, Kozlakidis Z, Zhong L, Heeschen C, Zheng XQ, Chen C, Zhang P, Wang H. The intratumor mycobiome promotes lung cancer progression via myeloid-derived suppressor cells. Cancer Cell. 2023 Nov 13;41(11):1927-1944.e9. doi: 10.1016/j.ccell.2023.08.012. Epub 2023 Sep 21.
PubMed 37738973Narunsky-Haziza L, Sepich-Poore GD, Livyatan I, Asraf O, Martino C, Nejman D, Gavert N, Stajich JE, Amit G, Gonzalez A, Wandro S, Perry G, Ariel R, Meltser A, Shaffer JP, Zhu Q, Balint-Lahat N, Barshack I, Dadiani M, Gal-Yam EN, Patel SP, Bashan A, Swafford AD, Pilpel Y, Knight R, Straussman R. Pan-cancer analyses reveal cancer-type-specific fungal ecologies and bacteriome interactions. Cell. 2022 Sep 29;185(20):3789-3806.e17. doi: 10.1016/j.cell.2022.09.005.
PubMed 36179670
Study at a glance
From the registry record, last updated by the sponsor on 25 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Study on the Microbial Environment of Non-small Cell Lung Cancer Based on Mycogenomics and Its Clinical Relevance
- ClinicalTrials.gov ID
- NCT07783971
- Acronym / sponsor ID
- microbial environment
- Conditions
- Fungal Diseases, Lung Cancer (NSCLC), Microbioata
- Keywords
- the lung microbiome
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 10 participants (estimated)
- Lead sponsor
- 958th Army Hospital of the Chinese People's Liberation ArmyUniversity, hospital or other
- Study start
- 1 Aug 2026 (actual)
- Primary completion
- 30 Jan 2028 (estimated)
- Study completion
- 1 Aug 2028 (estimated)
- First posted
- 25 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to uncover the characteristics of the fungal flora in non-small cell lung cancer, and to investigate the relationship between pulmonary fungi and the various pathological subtypes, stages, clinical features of non-small cell lung cancer, as well as patient prognosis. It seeks to provide new perspectives for a comprehensive understanding of non-small cell lung cancer, as well as new approaches for its early diagnosis and prognosis assessment.
Detailed description
This project intends to study the structural characteristics and clinical relevance of fungal microbiota in lung tissue of patients with non-small cell lung cancer. The project plans to collect 500 lung tissue samples from patients undergoing lung cancer surgery, build an ecological map of non-small cell lung cancer fungi through high-throughput sequencing, and simultaneously carry out traditional fungi culture to obtain culturable strain resources, so as to build a resource bank of non-small cell lung cancer fungi. By integrating clinicopathological information and follow-up data, using bioinformatics and statistical methods, key landmark fungi were screened, and the correlation between fungal community structure and different pathological subtypes, stages and clinical characteristics of non-small cell lung cancer was analyzed.
This project intends to study the structural characteristics and clinical relevance of fungal microbiota in lung tissue of patients with non-small cell lung cancer. The project plans to collect 500 lung tissue samples from patients undergoing lung cancer surgery, build an ecological map of non-small cell lung cancer fungi through high-throughput sequencing, and simultaneously carry out traditional fungi culture to obtain culturable strain resources, so as to build a resource bank of non-small cell lung cancer fungi. By integrating clinicopathological information and follow-up data, using bioinformatics and statistical methods, key landmark fungi were screened, and the correlation between fungal community structure and different pathological subtypes, stages and clinical characteristics of non-small cell lung cancer was analyzed.
Study design
- Observational model
- Case-control
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Lung cancer group | – | –The samples included in this group were lung cancer tissues. |
| Normal lung tissue group | – | –The samples included in this group were normal lung tissues. |
Who may qualify
- Ages
- 30 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The research object is the patients who are newly diagnosed as "non-small cell lung cancer" and intend to undergo surgical resection
Key inclusion criteria (1 listed)
- Non-small cell lung cancer was diagnosed by biopsy before operation, frozen pathology during operation or paraffin section after operation; The patients were 30 to 80 years old; No chemotherapy, radiotherapy, targeted therapy or immunotherapy were given before operation;
Key exclusion criteria (1 listed)
- Patients who do not meet the inclusion criteria; Combined with primary malignant tumor of other systems or recurrence of lung cancer, combined with immunodeficiency disease; Acute exacerbation of chronic obstructive pulmonary disease, bronchial asthma, bronchiectasis with infection, tuberculosis and pneumoconiosis; recent use of antifungal drugs; Basic clinical information (such as pathological type, clinical stage and treatment plan) cannot be obtained;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
the fungal microbial environment
Time frame: baseline, pre-surgery
Different fungal microbial environments were observed in different parts of lung tissue.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Aug 2026.
- Background: PubMed 36179671Dohlman AB, Klug J, Mesko M, Gao IH, Lipkin SM, Shen X, Iliev ID. A pan-cancer mycobiome analysis reveals fungal involvement in gastrointestinal and lung tumors. Cell. 2022 Sep 29;185(20):3807-3822.e12. doi: 10.1016/j.cell.2022.09.015.
- Background: PubMed 37738973Liu NN, Yi CX, Wei LQ, Zhou JA, Jiang T, Hu CC, Wang L, Wang YY, Zou Y, Zhao YK, Zhang LL, Nie YT, Zhu YJ, Yi XY, Zeng LB, Li JQ, Huang XT, Ji HB, Kozlakidis Z, Zhong L, Heeschen C, Zheng XQ, Chen C, Zhang P, Wang H. The intratumor mycobiome promotes lung cancer progression via myeloid-derived suppressor cells. Cancer Cell. 2023 Nov 13;41(11):1927-1944.e9. doi: 10.1016/j.ccell.2023.08.012. Epub 2023 Sep 21.
- Background: PubMed 36179670Narunsky-Haziza L, Sepich-Poore GD, Livyatan I, Asraf O, Martino C, Nejman D, Gavert N, Stajich JE, Amit G, Gonzalez A, Wandro S, Perry G, Ariel R, Meltser A, Shaffer JP, Zhu Q, Balint-Lahat N, Barshack I, Dadiani M, Gal-Yam EN, Patel SP, Bashan A, Swafford AD, Pilpel Y, Knight R, Straussman R. Pan-cancer analyses reveal cancer-type-specific fungal ecologies and bacteriome interactions. Cell. 2022 Sep 29;185(20):3789-3806.e17. doi: 10.1016/j.cell.2022.09.005.
- The project has been put on record in China medical research filing system.Link provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for Fungal Diseases
RecruitingObservational study
Studies of Disorders With Increased Susceptibility to Fungal Infections
Fungal Infections, Primary Immune Deficiencies
Not yet recruitingPhase 4
Emerging Indications for Hyperbaric Oxygen Treatment
Post-COVID-19 Condition, Ulcerative Colitis
Not yet recruitingObservational study
mNGS for IFD in Patients With Hematological Malignancies
Hematological Malignancies, Invasive Fungal Disease
RecruitingObservational study
Low-Dose Liposomal Amphotericin B for Invasive Fungal Infection Prophylaxis in Neutropenic Children
Thalassemia, Hematopoietic Stem Cell Transplantation
RecruitingObservational study
Derivation and Validation of the Fungal Pneumonia Assessment and Likelihood Predictor Score
Pneumonia, Fungal Pneumonia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Fungal Diseases and Lung Cancer (NSCLC), run by 958th Army Hospital of the Chinese People's Liberation Army at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 25 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact shunhong wang project leader (023-68762084, wangshunhong918@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
the fungal microbial environment (time frame: baseline, pre-surgery). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07783971, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Aug 2026; AzTrials last refreshed its copy on 1 Nov 2026.